195 related articles for article (PubMed ID: 23474343)
1. Neoadjuvant chemotherapy prior to pelvic exenteration in patients with recurrent cervical cancer: single institution experience.
Landoni F; Zanagnolo V; Rosenberg PG; Lopes A; Radice D; Bocciolone L; Aletti G; Parma G; Colombo N; Maggioni A
Gynecol Oncol; 2013 Jul; 130(1):69-74. PubMed ID: 23474343
[TBL] [Abstract][Full Text] [Related]
2. Indications for primary and secondary exenterations in patients with cervical cancer.
Marnitz S; Köhler C; Müller M; Behrens K; Hasenbein K; Schneider A
Gynecol Oncol; 2006 Dec; 103(3):1023-30. PubMed ID: 16890276
[TBL] [Abstract][Full Text] [Related]
3. Pelvic exenteration affords safe and durable treatment for locally advanced rectal carcinoma.
Gannon CJ; Zager JS; Chang GJ; Feig BW; Wood CG; Skibber JM; Rodriguez-Bigas MA
Ann Surg Oncol; 2007 Jun; 14(6):1870-7. PubMed ID: 17406945
[TBL] [Abstract][Full Text] [Related]
4. Does intra-operative radiation at the time of pelvic exenteration improve survival for patients with recurrent, previously irradiated cervical, vaginal, or vulvar cancer?
Backes FJ; Billingsley CC; Martin DD; Tierney BJ; Eisenhauer EL; Cohn DE; O'Malley DM; Salani R; Copeland LJ; Fowler JM
Gynecol Oncol; 2014 Oct; 135(1):95-9. PubMed ID: 25084510
[TBL] [Abstract][Full Text] [Related]
5. Indications and long-term clinical outcomes in 282 patients with pelvic exenteration for advanced or recurrent cervical cancer.
Schmidt AM; Imesch P; Fink D; Egger H
Gynecol Oncol; 2012 Jun; 125(3):604-9. PubMed ID: 22406639
[TBL] [Abstract][Full Text] [Related]
6. Resectability rates of previously irradiated recurrent cervical cancer (PIRCC) treated with pelvic exenteration: is still the clinical involvement of the pelvis wall a real contraindication? a twenty-year experience.
Jurado M; Alcázar JL; Martinez-Monge R
Gynecol Oncol; 2010 Jan; 116(1):38-43. PubMed ID: 19878978
[TBL] [Abstract][Full Text] [Related]
7. Pelvic exenteration for recurrent squamous cell carcinoma of the pelvic organs arising from the cloaca--a single institution's experience over 16 years.
Tan KK; Pal S; Lee PJ; Rodwell L; Solomon MJ
Colorectal Dis; 2013; 15(10):1227-31. PubMed ID: 23714581
[TBL] [Abstract][Full Text] [Related]
8. Does histologic type correlate to outcome after pelvic exenteration for cervical and vaginal cancer?
Baiocchi G; Guimaraes GC; Faloppa CC; Kumagai LY; Oliveira RA; Begnami MD; Soares FA; Lopes A
Ann Surg Oncol; 2013 May; 20(5):1694-700. PubMed ID: 23212765
[TBL] [Abstract][Full Text] [Related]
9. Pelvic exenteration for adenocarcinoma of the uterine cervix.
Crozier M; Morris M; Levenback C; Lucas KR; Atkinson EN; Wharton JT
Gynecol Oncol; 1995 Jul; 58(1):74-8. PubMed ID: 7789894
[TBL] [Abstract][Full Text] [Related]
10. [Robot-assisted laparoscopy in the management of recurrent pelvic cancer].
Jauffret C; Lambaudie E; Bannier M; Buttarelli M; Houvenaeghel G
Gynecol Obstet Fertil; 2011 Dec; 39(12):674-80. PubMed ID: 21871833
[TBL] [Abstract][Full Text] [Related]
11. Preoperative hyperfractionated chemoradiation for locally recurrent rectal cancer in patients previously irradiated to the pelvis: A multicentric phase II study.
Valentini V; Morganti AG; Gambacorta MA; Mohiuddin M; Doglietto GB; Coco C; De Paoli A; Rossi C; Di Russo A; Valvo F; Bolzicco G; Dalla Palma M;
Int J Radiat Oncol Biol Phys; 2006 Mar; 64(4):1129-39. PubMed ID: 16414206
[TBL] [Abstract][Full Text] [Related]
12. [Comparative analysis of neoadjuvant therapies in stage Ib2 and IIa2 cervical carcinoma].
Hu JL; Wu LY; Li N; Li XG; Huang MN; Zhang R
Zhonghua Fu Chan Ke Za Zhi; 2012 Jun; 47(6):452-7. PubMed ID: 22932113
[TBL] [Abstract][Full Text] [Related]
13. Indications and outcome of pelvic exenteration for locally advanced primary and recurrent rectal cancer.
Bhangu A; Ali SM; Brown G; Nicholls RJ; Tekkis P
Ann Surg; 2014 Feb; 259(2):315-22. PubMed ID: 23478530
[TBL] [Abstract][Full Text] [Related]
14. The toxicity and long-term efficacy of nedaplatin and paclitaxel treatment as neoadjuvant chemotherapy for locally advanced cervical cancer.
Yin M; Zhang H; Li H; Li X; Liu Y; Chen X; Lou G; Li K
J Surg Oncol; 2012 Feb; 105(2):206-11. PubMed ID: 21815150
[TBL] [Abstract][Full Text] [Related]
15. Five-year experience with combined operative and radiotherapeutic treatment of recurrent gynecologic tumors infiltrating the pelvic wall.
Höckel M; Sclenger K; Hamm H; Knapstein PG; Hohenfellner R; Rösler HP
Cancer; 1996 May; 77(9):1918-33. PubMed ID: 8646694
[TBL] [Abstract][Full Text] [Related]
16. Ileal orthotopic neobladder after pelvic exenteration for cervical cancer.
Chiva LM; Lapuente F; Núñez C; Ramírez PT
Gynecol Oncol; 2009 Apr; 113(1):47-51. PubMed ID: 19176235
[TBL] [Abstract][Full Text] [Related]
17. Pelvic exenteration: ten-year experience at the European Institute of Oncology in Milan.
Maggioni A; Roviglione G; Landoni F; Zanagnolo V; Peiretti M; Colombo N; Bocciolone L; Biffi R; Minig L; Morrow CP
Gynecol Oncol; 2009 Jul; 114(1):64-8. PubMed ID: 19411097
[TBL] [Abstract][Full Text] [Related]
18. Clinical outcome of pelvic exenteration in patients with advanced or recurrent uterine cervical cancer.
Tanaka S; Nagase S; Kaiho-Sakuma M; Nagai T; Kurosawa H; Toyoshima M; Tokunaga H; Otsuki T; Utsunomiya H; Takano T; Niikura H; Ito K; Yaegashi N
Int J Clin Oncol; 2014 Feb; 19(1):133-8. PubMed ID: 23404487
[TBL] [Abstract][Full Text] [Related]
19. Predictors for long-term survival after interdisciplinary salvage surgery for advanced or recurrent gynecologic cancers.
Fleisch MC; Pantke P; Beckmann MW; Schnuerch HG; Ackermann R; Grimm MO; Bender HG; Dall P
J Surg Oncol; 2007 May; 95(6):476-84. PubMed ID: 17192947
[TBL] [Abstract][Full Text] [Related]
20. Postoperative pelvic intensity-modulated radiotherapy and concurrent chemotherapy in intermediate- and high-risk cervical cancer.
Folkert MR; Shih KK; Abu-Rustum NR; Jewell E; Kollmeier MA; Makker V; Barakat RR; Alektiar KM
Gynecol Oncol; 2013 Feb; 128(2):288-93. PubMed ID: 23159818
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
